NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 82 resultados LastUpdate Última actualización 05/02/2023 [08:36:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 4 nextPage   por página


CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN

NºPublicación: US2023030998A1 02/02/2023

Solicitante:

THE U S A AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES [US]

US_2023002776_A1

Resumen de: US2023030998A1

The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.

traducir

TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT

NºPublicación: US2023031954A1 02/02/2023

Solicitante:

TETRAPHASE PHAMACEUTICALS INC [US]

MX_2019002453_A

Resumen de: US2023031954A1

The present invention is directed to methods of treating hematological cancers, such as acute myleiod leukemia, with tetracyclines, or a pharmaceutically acceptable salt thereof.

traducir

MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF

NºPublicación: WO2023009833A1 02/02/2023

Solicitante:

CHILDRENS HOSPITAL MEDICAL CENTER [US]
THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES
KUROME THERAPEUTICS INC

Resumen de: WO2023009833A1

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

traducir

Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells

NºPublicación: AU2022287584A1 02/02/2023

Solicitante:

CELULARITY INC

Resumen de: AU2022287584A1

Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells. In certain embodiments, the NK cells produced by the three-stage methods described herein are used in combination with IL

traducir

Antiproliferative compounds and methods of use thereof

NºPublicación: AU2022287569A1 02/02/2023

Solicitante:

CELGENE CORP

US_2022280505_PA

Resumen de: AU2022287569A1

Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin- 4 yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.

traducir

METHODS FOR TREATING ACUTE MYELOID LEUKEMIA WITH ANTI-ILT3 ANTIBODIES

NºPublicación: WO2023009434A1 02/02/2023

Solicitante:

MERCK SHARP & DOHME LLC [US]
WU CAI [US]
ZHANG DAPING [US]
ZHANG HOOVER JIE [US]

Resumen de: WO2023009434A1

This disclosure relates to methods for treating cancer in a subject identified as having acute myeloid leukemia (AML), comprising administering an anti-ILT3 antigen binding protein, or antigen binding fragment to the patient every three weeks (Q3W).

traducir

PREPARATION AND APPLICATION OF AMINOPYRIMIDINE DERIVATIVE SELECTIVELY TARGETING CDK9

NºPublicación: WO2023005280A1 02/02/2023

Solicitante:

CHINA PHARMACEUTICAL UNIV [CN]

Resumen de: WO2023005280A1

Disclosed in the present invention are preparation and application of an aminopyrimidine derivative selectively targeting CDK9. Also disclosed in the present invention are a preparation method for the compound and an application of the compound in prevention and/or treatment of tumor-related diseases including glioma, various leukemia, lymphoma, liver cancer, stomach cancer, prostate cancer, ovarian cancer, breast cancer, lung cancer and the like. The compound can effectively and selectively inhibit the activity of CDK9 protein, and meanwhile, the compound shows remarkable anti-tumor activity in cancer cells such as MV4-11, MCF-7 and MOLM-13.

traducir

PREPARATION METHOD FOR AND APPLICATION OF NOVEL CDK9 INHIBITOR HAVING MACROCYCLIC SKELETON STRUCTURE

NºPublicación: WO2023005281A1 02/02/2023

Solicitante:

CHINA PHARMACEUTICAL UNIV [CN]

Resumen de: WO2023005281A1

Disclosed are a preparation method for and an application of a novel CDK9 inhibitor having a macrocyclic skeleton structure (I). The compound can effectively inhibit the activity of CDK9 protein and has high selectivity for CDK9. Also disclosed are a preparation method for the compound and an application thereof in preventing and/or treating tumor-related diseases, comprising glioma, various types of leukemia, lymphoma, liver cancer, gastric cancer, prostate cancer, ovarian cancer, breast cancer, lung cancer, etc.

traducir

SMALL MOLECULE INHIBITION OF DEUBIQUITINATING ENZYME JOSEPHIN DOMAIN CONTAINING 1 (JOSD1) AS A TARGETED THERAPY FOR LEUKEMIAS WITH MUTANT JANUS KINASE 2 (JAK2)

NºPublicación: WO2023009982A1 02/02/2023

Solicitante:

DANA FARBER CANCER INST INC [US]
BUHRLAGE SARA [US]
GRIFFIN JAMES [US]
WEISBERG ELLEN [US]
YANG JING [US]
LIU XIAOXI [US]
MAGIN ROBERT [US]
HU BIN [US]
CHAN WAI CHEUNG [US]

Resumen de: WO2023009982A1

Disclosed are deubiquitinase (DUB) JOSD1 inhibitors and methods of treating a disease or disorder mediated by dysregulated Janus Kinase 2 (JAK2) activity, in a subject in need thereof, comprising administering a therapeutically effective amount of one or more DUB inhibitors.

traducir

MYELOMA BIOMARKER LGALS3BP AND USE THEREOF

NºPublicación: WO2023004624A1 02/02/2023

Solicitante:

BEIJING SUNBIO BIOTECH CO LTD [CN]

Resumen de: WO2023004624A1

Provided are a product for detecting an LGALS3BP gene or an LGALS3BP protein and the use thereof in the preparation of a tool for the diagnosis and/or prognosis of myeloma. Further provided are an inhibitor of the LGALS3BP gene or the LGALS3BP protein and the use thereof in the preparation of a drug for the treatment of myeloma.

traducir

MYELOMA BIOMARKER SERPINF2 AND USE THEREOF

NºPublicación: WO2023004626A1 02/02/2023

Solicitante:

BEIJING SUNBIO BIOTECH CO LTD [CN]

Resumen de: WO2023004626A1

The present invention relates to the technical fields of molecular biology and biomedicine, and specifically relates to a myeloma biomarker and the use thereof. According to the above-mentioned use of the present invention, whether a subject has myeloma, or whether the subject is at a risk of having myeloma, or whether the prognosis of the subject is good can be judged by means of detecting an expression level of an SERPINF2 gene or an SERPINF2 protein in a subject, thereby guiding a clinician to provide an effective prevention means or treatment regimen for the subject, which is beneficial for improving the survival rate of the subject.

traducir

Satraplatin for use in the treatment of lymphoid neoplasms

NºPublicación: AU2021306808A1 02/02/2023

Solicitante:

DAYTON THERAPEUTICS AG

WO_2022008149_PA

Resumen de: AU2021306808A1

The present invention relates to satraplatin for use in a method of treating a malignancy of the lymphoid tissue in a mammal, preferably a human, and in particular of a malignancy of the lymphoid tissue with primary or secondary central nervous system (CNS) manifestation such as primary diffuse large B cell lymphoma of the CNS.

traducir

Endothelial cells for mitigation of chemotherapy-induced toxicity

NºPublicación: AU2021297353A1 02/02/2023

Solicitante:

ANGIOCRINE BIOSCIENCE INC

WO_2021263189_A1

Resumen de: AU2021297353A1

The present invention provides compositions and methods for the mitigation of side effects of chemotherapy, for example in human subjects with hematologic malignancies (such as lymphoma, leukemia and myelodysplastic syndrome) as well as subjects with other malignancies or other conditions that may be treated with chemotherapy, such as high dose therapy (HOT) or a combination of high dose HDT and a hematopoietic stem cell transplant. The methods comprise administration of endothelial cells, such as engineered human umbilical vein endothelial cells engineered to express the adenoviral E40RF1 protein (E40RF1+ HUVECs), to human subjects. The side effects mitigated by the compositions and methods of the invention include, but are not limited to, oral / gastrointestinal side effects and febrile neutropenia.

traducir

CHIMERIC ANTIGEN RECEPTORS FOR TREATMENT OF CANCER

NºPublicación: WO2023010126A2 02/02/2023

Solicitante:

VOR BIOPHARMA INC [US]
CHAKRABORTY TIRTHA [US]

Resumen de: WO2023010126A2

Provided herein are chimeric antigen receptors (CARs) with binding specificity for CD123. Nucleic acids, expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are also disclosed, and methods including the treatment of a hematopoietic malignancy or premalignancy characterized by the expression of CD123, e.g., leukemias such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

traducir

IL15/IL15R ALPHA HETERODIMERIC FC-FUSION PROTEINS FOR THE TREATMENT OF BLOOD CANCERS

NºPublicación: WO2023010031A1 02/02/2023

Solicitante:

GENENTECH INC [US]
XENCOR INC [US]

Resumen de: WO2023010031A1

The present disclosure provides methods of treating a blood cancer, such as multiple myeloma, by administering a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15Rα protein-Fc domain fusion.

traducir

Use of bispecific CD123 x CD3 diabodies for the treatment of hematologic malignancies

NºPublicación: AU2021293006A1 02/02/2023

Solicitante:

MACROGENICS INC
NOTTINGHAM TRENT UNIV

BR_112022025834_PA

Resumen de: AU2021293006A1

The present invention is directed to a method of treating a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including hematologic malignancies that are refractive to chemotherapeutic and/or hypomethylating agents. The method concerns administering a CD123 x CD3 bispecific binding molecule to a patient in an amount effective to stimulate the killing of cells of said hematologic malignancy in said patient. The present invention is particularly directed to the embodiment of such method in which a cellular sample from the patient prior to such administration evidences an expression of one or more target genes that is increased relative to a baseline level of expression of such genes, for example, a baseline level of expression of such genes in a reference population of individuals who are suffering from the hematologic malignancy, or with respect to the level of expression of a reference gene.

traducir

Composition for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

NºPublicación: AU2021275055A1 02/02/2023

Solicitante:

JUMAA \u200BWEINACHT HASSAN
JUMAA MOUHANNAD

WO_2021236691_A1

Resumen de: AU2021275055A1

The present invention provides compositions comprising antibodies to interleukin 7 receptor (IL7R), as well methods for treatment using the IL7R antibodies.

traducir

Methods for treating multiple myeloma

NºPublicación: AU2021272291A1 02/02/2023

Solicitante:

JANSSEN BIOTECH INC

BR_112022022800_PA

Resumen de: AU2021272291A1

Methods of treating cancers using a BCMAxCD3 bispecific antibody are described.

traducir

Compositions and methods for treating cancer

NºPublicación: AU2021271971A1 02/02/2023

Solicitante:

ADAGENE AG

WO_2021228178_A1

Resumen de: AU2021271971A1

The present application provides compositions and methods for treating cancers, including follicular lymphoma, T cell lymphoma and adenoid cystic carcinoma, using an anti-CD137 antibody that specifically binds to an extracellular domain of human CD137. In some embodiment, combination therapies including the anti-CD137 antibody and an immune checkpoint inhibitor, and/or a chemotherapeutic agent are provided. Biomarkers such as total CD137, membrane bound CD137 (mCD137), soluble CD137 (sCD137), CD137 ligand, Ki67, CD8+ effector memory T (T

traducir

Reverse Transcriptase Mutants with Increased Activity and Thermostability

NºPublicación: US2023031558A1 02/02/2023

Solicitante:

INTEGRATED DNA TECHONOLGIES INC [US]

WO_2022020371_A2

Resumen de: US2023031558A1

The disclosure provides Moloney murine leukemia virus (MMLV) reverse transcriptase (RTase) mutants. The disclosure as provides suitable amino acid positions in MMLV RTase for mutagenesis and methods and kits for using MMLV RTase mutants to synthesize cDNA from RNA templates.

traducir

Assays and methods for selecting a treatment regimen for a subject with leukemia

NºPublicación: AU2022291559A1 02/02/2023

Solicitante:

CELATOR PHARMACEUTICALS INC
OREGON HEALTH & SCIENCE UNIV

CN_115414376_A

Resumen de: AU2022291559A1

Abstract Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.

traducir

Use of chloro-{N-ethyl-N'-phenyl(pyridin-2-yl)methylidenecarbamohydrazonothioato}copper as a human myeloid leukemia HL-60 cells proliferation inhibitor

NºPublicación: MD20210046A1 31/01/2023

Solicitante:

UNIV DE STAT DIN MOLDOVA [MD]

Resumen de: MD20210046A1

The invention relates to chemistry and medicine, in particular to the use of a copper coordination compound of the class of transition metal thiosemicarbazonates as a human myeloid leukemia HL-60 cells proliferation inhibitor and can be used in medicine in the treatment of leukemia.According to the invention, claimed is the use as a human myeloid leukemia HL-60 cells proliferation inhibitor of chloro-{N-ethyl-N'-[phenyl(pyridin-2-yl)methylidene]carbamohydrazonothioato}copper of the formula:.Said compound expands the arsenal of inhibitors of human myeloid leukemia HL-60 cells with high biological activity.

traducir

METHODS

NºPublicación: US2023026111A1 26/01/2023

Solicitante:

AUTOLUS LTD [GB]

US_2023018688_PA

Resumen de: US2023026111A1

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

traducir

TREATMENT OF HEMATOLOGICAL MALIGNANCY

NºPublicación: WO2023002362A1 26/01/2023

Solicitante:

PFIZER [US]

Resumen de: WO2023002362A1

This invention relates to therapies useful for the treatment of hematological malignancies. In particular the invention relates to a method of treating acute myeloid leukemia (AML) in a patient in need thereof, wherein said patient is positive for at least one mutation of the FLT3 gene, said method comprising administering to said patient a smoothened inhibitor, or a pharmaceutically acceptable salt thereof, in combination with azacitidine, thereby treating said acute myeloid leukemia. The invention also relates to associated combination therapies, pharmaceutical compositions, pharmaceutical uses and kits.

traducir

EP300/CBP INHIBITOR

Nº publicación: US2023027088A1 26/01/2023

Solicitante:

HINOVA PHARMACEUTICALS INC [CN]

JP_2022549471_PA

Resumen de: US2023027088A1

An EP300/CBP inhibitor, specifically provided is a compound as shown in formula I, or a deuterated product thereof, or a salt thereof, or a conformational isomer thereof, or a crystal form thereof, or a solvate thereof. The compound is highly selective for EP300/CBP, and can effectively inhibit the activity of EP300/CBP; in addition, the compound has an excellent inhibitory effect on various tumor cells including prostate cancer cells, leukemia cells, breast cancer cells and multiple myeloma cells. The compound has broad application prospects in the preparation of an EP300/CBP inhibitor, and drugs for preventing and/or treating tumors, myeloid hematopoietic stem/progenitor cells malignant disease, and regulating regulatory T cells.

traducir

Página1 de 4 nextPage por página

punteroimgVolver